2,3 REDEFINE 1 was a 68-week, double-blind, randomized, placebo- and active-controlled phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus cagrilintide 2.4 mg monotherapy, semaglutide 2.4 mg monotherapy, and placebo, all in combination with lifestyle intervention in 3,417 adults with obesity or overweight with one or more obesity-related complications and without type 2 diabetes
Historically, data on population demographics across clinical trials have not been consistently reported, particularly prior to the 2017 guidance, which requires reporting by sex/gender, race, and/or ethnicity in applicable clinical trials
We stripped away the guesswork and replaced it with strict in-house protocols and verified data
CBT-I (Cognitive Behavioral Therapy for Insomnia) Mechanism: Behavioral/psychological intervention with the strongest long-term evidence for chronic insomnia